相关实验视频
Updated: Aug 7, 2026

08:33
An Ex vivo Culture System to Study Thyroid Development
Published on: June 6, 2014
在患有格雷夫斯病的患者接受抗甲状腺药物治疗之前,期间和之后,循环免疫复合物和激发甲状腺的免疫球蛋白
Lancet (London, England)
|June 28, 1980
概括
循环免疫复合体 (CIC) 可能掩盖甲状腺刺激免疫球蛋白 (TSI) 在格雷夫斯病. 治疗期间的CIC发展与TSI消失相关,表明恢复免疫耐受性.
科学领域:
- 内分泌学 在内分泌学.
- 免疫学 免疫学 免疫学
- 自免疫性疾病 自免疫性疾病
背景情况:
- 格雷夫斯病是一种自身免疫性疾病,其特征是产生的甲状腺刺激性免疫球蛋白 (TSI).
- 循环免疫复合体 (CIC) 在格雷夫斯病的发病和监测中的作用仍然不完全理解.
研究的目的:
- 在患有格雷夫斯病的患者中研究 TSI 和 CIC 水平之间的关系.
- 评估抗甲状腺药物治疗对 TSI 和 CIC 的影响.
- 探索CIC在格雷夫斯病中免疫耐受性发展中的潜在作用.
主要方法:
- 来自57名未经治疗的格雷夫斯病患者的血清被分析为TSI和CIC.
- 在接受抗甲状腺药物治疗之前,期间和之后收集了样本.
- 使用已建立的实验室分析量化了TSI指数和CIC存在.
主要成果:
- 在未接受治疗的患者中,72%的TSI呈阳性,30%的CIC. 患有负TSI的患者中,CIC的患病率更高.
- 在早期治疗期间,85%的患者患有CIC,这与TSI的消失相吻合.
- 即使在CIC在治疗后不再检测到之后,TSI也没有重新出现.
结论:
- 循环的免疫复合体可能会干扰Graves病中TSI的检测.
- 在治疗期间CIC的发展可能意味着对TSH受体的免疫耐受性恢复.
- 这表明在Graves病中,有潜在的缓解机制.
相关概念视频
Allergic Drug Reactions
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing numerous...
Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drug Toxicity: Allergic Reactions
Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...
Graves Disease II: Pathophysiology
Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...
Hypersensitivity Reactions: Immune-Complex Reactions
Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum sickness, a systemic...

